JP2022536935A5 - - Google Patents
Info
- Publication number
- JP2022536935A5 JP2022536935A5 JP2021574918A JP2021574918A JP2022536935A5 JP 2022536935 A5 JP2022536935 A5 JP 2022536935A5 JP 2021574918 A JP2021574918 A JP 2021574918A JP 2021574918 A JP2021574918 A JP 2021574918A JP 2022536935 A5 JP2022536935 A5 JP 2022536935A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hiv
- cells
- once
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962862432P | 2019-06-17 | 2019-06-17 | |
| US62/862,432 | 2019-06-17 | ||
| PCT/US2020/038177 WO2020257309A1 (en) | 2019-06-17 | 2020-06-17 | Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536935A JP2022536935A (ja) | 2022-08-22 |
| JP2022536935A5 true JP2022536935A5 (cg-RX-API-DMAC7.html) | 2023-06-15 |
| JP7612617B2 JP7612617B2 (ja) | 2025-01-14 |
Family
ID=74040889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574918A Active JP7612617B2 (ja) | 2019-06-17 | 2020-06-17 | 細胞性免疫及び体液性免疫を誘導するための同種異系t細胞ベースのhivワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210030795A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3982981A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7612617B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220084006A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114269356A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020294700A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025286A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143599A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288945A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015643A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020257309A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022192086A1 (en) * | 2021-03-06 | 2022-09-15 | Gumrukcu Serhat | Compositions and methods for treating and preventing coronavirus infections |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| US6139832A (en) * | 1995-02-08 | 2000-10-31 | Human Genome Sciences, Inc. | Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides |
| US6569418B1 (en) * | 1997-12-11 | 2003-05-27 | University Of Maryland Biotechnology Institute | Immuno-modulating effects of chemokines in DNA vaccination |
| DE60116075T4 (de) * | 2000-04-25 | 2007-06-06 | Immunex Corp., Thousand Oaks | Behandlung von tumoren mit photodynamischer therapie |
| GB0108065D0 (en) * | 2001-03-30 | 2001-05-23 | Syngenix Ltd | Viral vectors |
| DE602005025005D1 (de) * | 2004-10-07 | 2011-01-05 | Argos Therapeutics Inc | Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung |
| US8178291B2 (en) * | 2005-02-18 | 2012-05-15 | Monogram Biosciences, Inc. | Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors |
| WO2008055354A1 (en) * | 2006-11-10 | 2008-05-15 | Université de Montréal | Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods |
| US9234175B2 (en) * | 2009-11-17 | 2016-01-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Creating bioengineered lymph nodes |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| SG10201808811QA (en) * | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| CN107530450A (zh) * | 2015-03-20 | 2018-01-02 | 宾夕法尼亚大学理事会 | 具有作为佐剂的cd40配体的疫苗 |
| CA3106403A1 (en) * | 2018-07-15 | 2020-01-23 | Enochian BioPharma, Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
| US20220370495A1 (en) * | 2019-08-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Immune cells for adoptive cell therapies |
-
2020
- 2020-06-17 MX MX2021015643A patent/MX2021015643A/es unknown
- 2020-06-17 JP JP2021574918A patent/JP7612617B2/ja active Active
- 2020-06-17 CN CN202080056674.7A patent/CN114269356A/zh active Pending
- 2020-06-17 KR KR1020227000923A patent/KR20220084006A/ko not_active Ceased
- 2020-06-17 EP EP20826762.5A patent/EP3982981A4/en not_active Withdrawn
- 2020-06-17 BR BR112021025286A patent/BR112021025286A2/pt unknown
- 2020-06-17 CA CA3143599A patent/CA3143599A1/en active Pending
- 2020-06-17 US US16/904,319 patent/US20210030795A1/en not_active Abandoned
- 2020-06-17 AU AU2020294700A patent/AU2020294700A1/en not_active Abandoned
- 2020-06-17 WO PCT/US2020/038177 patent/WO2020257309A1/en not_active Ceased
-
2021
- 2021-12-13 IL IL288945A patent/IL288945A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westervelt et al. | Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo | |
| AU2018283811B2 (en) | Poxvirus vectors encoding HIV antigens, and methods of use thereof | |
| JP2004537974A5 (cg-RX-API-DMAC7.html) | ||
| US20240141374A1 (en) | On demand expression of exogenous factors in lymphocytes | |
| Spearman | HIV vaccine development: lessons from the past and promise for the future | |
| Zubair et al. | Clinical trials and recent progress in HIV vaccine development | |
| De Goede et al. | Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection | |
| Ao et al. | Development and evaluation of an Ebola virus glycoprotein mucin-like domain replacement system as a new dendritic cell-targeting vaccine approach against HIV-1 | |
| Titti et al. | Problems and emerging approaches in HIV/AIDS vaccine development | |
| Kirchhoff et al. | A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses | |
| Rollman et al. | The rationale behind a vaccine based on multiple HIV antigens | |
| Young et al. | Particle-based vaccines for HIV-1 infection | |
| AU2005243730B2 (en) | Method of using adenoviral vectors to induce an immune response | |
| WO1993008836A1 (en) | Induction of protection against viral infection by synergy between viral proteins and viral peptides | |
| Lemiale et al. | Lentiviral vectors for HIV disease prevention and treatment | |
| Persson et al. | Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity | |
| zur Megede et al. | A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques | |
| Kraus et al. | Characterization of a molecular clone of HIV type 2 infectious for Macaca nemestrina | |
| AU718143B2 (en) | Human immunodeficiency virus vaccines and therapeutics containing replication-impaired HIV-1 NEF-deletion mutants | |
| WO2017088053A1 (en) | Dual-action vaccines (dav) to prevent hiv and ebola virus infections | |
| Sheppard et al. | The prospects for vaccines against HIV-1: more than a field of long-term nonprogression? | |
| Singh et al. | HIV vaccine development | |
| Zagury et al. | In vitro characterization of a biologically active molecular clone of HIV-2NIH-Z containing a nef deletion and expressing a full-length transmembrane protein | |
| Kraiselburd | Biology of HIV replication | |
| Warner et al. | Human immunodeficiency virus immunotherapy using a retroviral vector |